<DOC>
	<DOCNO>NCT01672463</DOCNO>
	<brief_summary>This open label Phase 1b clinical trial IV administration OKN-007 pilot cohort human recurrent malignant glioma patient . All patient previously treat standard-of-care treatment include surgical resection , radiation chemotherapy , case treatment recurrent disease investigational agent bevacizumab ( Avastin ) . Patients unequivocal recurrence ( first great ) establish MRI without contrast ( e.g. , Gd-DTPA ( Gadolinium-diethylene triamine pentacetic acid ) meeting inclusion exclusion criterion , eligible OKN-007 treatment protocol .</brief_summary>
	<brief_title>Clinical Trial IV OKN-007 Pilot Cohort Human Recurrent Malignant Glioma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Confirmed histopathology WHO grade III glioma WHO grade IV GBM primary diagnosis 2 . Unequivocal radiographic evidence tumor progression MRI within 14 day prior registration 3 . Prior radiotherapy 4 . Prior Temozolomide treatment 5 . Last cytotoxic chemotherapy 28 day biologic therapy treatment 14 day study start ( great equal 42 day nitrosourea administer ) 6 . Karnofsky performance status great equal 60 % 7 . Full recovery ( &lt; grade 1 ) toxic effect earlier intervention minimum 28 day administration investigational agent 8 . Adequate renal , liver bone marrow function : Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Total bilirubin within normal limit AST / ALT ( SGPT ) &lt; 2.5 x ULN Creatinine within normal limit 9 . Patients must &gt; _18 year age 1 . Second primary malignancy ( except adequately treat basal cell carcinoma skin ) . Patients another malignancy past , free active disease 2 year , eligible 2 . Have receive treatment within last 28 day drug receive regulatory approval indication time study entry 3 . Serious concomitant systemic disorder ( example , active infection abnormal electrocardiogram ( ECG ) indicative cardiac disease ) , opinion investigator , would compromise safety patient his/her ability complete study 4 . Patients moderate severe renal impairment ( calculated creatinine clearance &lt; 60 mL/min ) 5 . Patients sodium , potassium , creatinine serum electrolytes &gt; grade 2 . 6 . Patients PT/PTT upper limit normal 7 . Screening ECG abnormality document investigator medically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>